Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
Authors
Keywords
-
Journal
eLife
Volume 5, Issue -, Pages -
Publisher
eLife Sciences Organisation, Ltd.
Online
2016-02-17
DOI
10.7554/elife.11999
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mitogen-activated Protein Kinase (MAPK) Hyperactivation and Enhanced NRAS Expression Drive Acquired Vemurafenib Resistance in V600E BRAF Melanoma Cells
- (2014) Michael Lidsky et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Towards a Unified Model of RAF Inhibitor Resistance
- (2014) D. B. Solit et al. Cancer Discovery
- An open investigation of the reproducibility of cancer biology research
- (2014) Timothy M Errington et al. eLife
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers
- (2012) A P Rebocho et al. ONCOGENE
- Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia
- (2011) Leisl M. Packer et al. CANCER CELL
- Mechanisms of Resistance to RAF Inhibitors in Melanoma
- (2011) Andrew E. Aplin et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth
- (2010) Josette Carnahan et al. MOLECULAR CANCER THERAPEUTICS
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
- (2010) F M Kaplan et al. ONCOGENE
- PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas
- (2010) John T. Lee et al. Pigment Cell & Melanoma Research
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started